Analysis of three properties of newcastle disease virus for fighting cancer: Tumor-selective replication, antitumor cytotoxicity, and immunostimulation

Methods in Molecular Biology

Volumn 797, Issue , 2012, Pages 177-204

  Fournier, Philippe ^a   Bian, Huijie ^b   Szeberényi, József ^c   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Apoptosis; Cytotoxicity; Endoplasmic reticulum stress; Immuno stimulatory action or immunostimulation; Immunotherapy; Newcastle disease virus; Selective replication, oncolytic; Tumor vaccination; Tumor cancer, transformed cells, hepatic stellate cells; Type I interferon; Viral oncolysis

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL; ARTICLE; CELL TRANSFORMATION; CYTOTOXICITY; CYTOTOXICITY TEST; ENDOPLASMIC RETICULUM STRESS; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; NEOPLASM; NEWCASTLE DISEASE PARAMYXOVIRUS; ONCOLYTIC VIROTHERAPY; TUMOR CELL LINE; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNIZATION; NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

AVES; HARNESS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

EID: 80555127442     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-340-0_13     Document Type: Chapter

References (44)

1. Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18:863–868.
2. Csatary LK. Viruses in the treatment of cancer. Lancet 1971; ii:825.
3. Alexander DJ, Allan WH. Newcastle disease virus pathotypes. Avian Path. 1974; 3(4): 269–278.
4. Lorence RM, Roberts MS, Groene WS, Rabin H. Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Hern aiz Driever P, Rabkin SD, eds. Replication-competent viruses for cancer therapy. Monographs in virology, Vol. 22. Basel, Switzerland: Karger, 2001:160–82.
5. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O’Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 2002; 20:2251–66.
6. Cassel WA, Murray DR, Olkowski ZL. Newcastle disease virus oncolysate in the management of stage III malignant melanoma. In: Sinkovics JG, Horvath JC, eds. Viral therapy of human cancer. New York: Marcel Dekker, 2005; 577–689.
7. Schirrmacher V, Fournier P. Newcastle Disease Virus: a promising vector for viral therapy of cancer. In: Harrington KJ, Pandha HS and Vile RG, eds. Viral therapy of cancer, vol 542. Wiley Publishers, 2008:171–186.
8. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 1992; 52(5): 448–453.
9. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V. Tumor-selective replication of Newcastle Disease Virus: association with defects of tumor cells defence. Int. J. Cancer 2006; 119(2): 328–38.
10. Li YL, Wu J, Wei D, Zhang DW, Feng H, Chen ZN, Bian H. Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibro-sis in mice. Liver Int. 2009; 29(4):593–602.
11. Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol. 2000; 16:1–15.
12. Apostolidis L, Schirrmacher V, Fournier P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int. J. Oncol. 2007; 31(5):1009–19.
13. Fábián Z, Csatary CM, Szeberényi J, Csatary LK. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J. Virol. 2007; 81(6):2817–30.
14. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus. Gene Ther. 1999; 6: 63–73.
15. Czeglédi A, Wehmann E, Lomniczi B. On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswar, and virulent strain Herts’33. Avian Pathol. 2003; 32, 271–276.
16. Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V. T-cell triggering by CD3-and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine. 2005; 23(19):2439–53.
17. Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther. 2005; 12:295–303.
18. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet. 1994; 8(2):171–6.
19. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 1994; 54(3):649–52.
20. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 2005; 115: 2656–2664.
21. Horvath CM. Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur. J. Biochem. 2004; 271:4621–8.
22. Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int. J. Oncol. 2009; 34(4): 971–82.
23. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B, Csatary CM. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. 2004; 67: 83–93.
24. Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res. 1999; 19:635–638.
25. Bai L, Koopmann J, Fiola C, Fournier P and Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int. J. Oncol. 2002; 21:685–694.
26. Bian H, Wilden H, Fournier P, Peeters B and Schirrmacher V. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Int. J. Oncol. 29: 1359–1369, 2006.
27. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001; 172:27–36.
28. Schirrmacher V, Griesbach A and Ahlert T. Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int. J. Oncol. 2001; 18:945–952.
29. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol. Med. 1998; 4(12):783–94.
30. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int. J. Oncol. 2002; 21:85–93.
31. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301–5.
32. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NK-k B by Toll-like receptor 3. Nature 2001; 413:732–8.
33. Fournier P, Zeng J, Schirrmacher V. Two ways to induce innate immune responses in human PBMCs. Paracrine stimulation of IFN-α responses by viral protein or dsRNA. Int. J. Oncol. 2003; 23:673–80.
34. Termeer CC, Schirrmacher V, Brocker EB, Becker JC. Newcastle Disease Virus infection induces a B7-1/B7-2 independent T cell-costimulatory activity in human melanoma cells. Cancer Gene Ther. 2000; 7:316–23.
35. Zeng J, Fournier P, Schirrmacher V. Induction of interferon-α and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle Disease Virus. Virology 2002; 297:19–30.
36. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. 2002; 14:129–35.
37. Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V, Walczak H. TNF-related apoptosis-inducing ligand mediates tumori-cidal activity of human monocytes stimulated by Newcastle disease virus. J. Immunol. 2003; 170:1814–21.
38. Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Int. J. Cancer. 2006; 118(3):658–67.
39. Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Hacker B, Schumacher M, Schirrmacher V. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J. Clin. Oncol. 1997; 15(4):1354–66.
40. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirrmacher V, Herold-Mende C. Anti-tumor vaccination of patients with glioblastoma multiforme: a pilot study to assess: Feasibility, safety and clinical benefit. J. Clin. Oncol 2004; 22 (21): 4272–4281.
41. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke BH, Weidauer H, Schirrmacher V, Herold-Mende C. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004; 64(21):8057–61.
42. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 2009; 58(1):61–9.
43. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved anti-tumor immune memory. Cancer Immunol. Immunother. 2005; 54(6): 587–598.
44. Aigner M, Janke M, Lulei M, Beckhove P, Fournier P, Schirrmacher V. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int. J. Oncol. 2008; 32(4):777–89.